Moderna - Latest News and Information
Technology Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
MRNA
Moderna is a biotechnology company focused on developing messenger RNA (mRNA)–based therapeutics and vaccines. It operates globally, including a presence in Germany with Moderna Germany GmbH in Munich, and emphasizes advancing the next generation of transformative medicines through its mRNA platform. The company highlights its mission to address unmet medical needs and bring innovative mRNA-based treatments to patients. The German page features information about the company’s mission, science of mRNA, and contact details for the Munich office.
Free Access to BioWorld Coronavirus Articles
Will Pfizer’s Lyme Disease Gamble Pay Off or Set the Space Back?
Healthtech, Biotech: Why the UK Is Emerging as an Essential Hub
Pfizer, BioNTech to Pause COVID Vaccine Study Due to Low Enrollment
STAT+: Novo Nordisk Strikes Deal with U.S. Startup to Develop Oral Obesity, Diabetes Drugs
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
The FDA’s Proposed “Black Box” Warning for COVID-19 Vaccines
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Stocks Making the Biggest Moves Midday: Moderna, Instacart, Rivian Automotive, DraftKings, Coinbase & More
ShinyHunters Group Targets Over 100 Enterprises, Including Canva, Atlassian, and Epic Games
FDA Backtracks On Moderna mRNA Flu Vaccine Refusal, Sets Aug. 5 Review Deadline
Moderna Says FDA Refuses to Review Its Application for Experimental Flu Shot
Rethinking Vaccine Production Platforms for Future Pandemics
Lilly Strikes Again, Buying CAR-T Firm Orna for $2.4bn
Vaccine Makers Curtail Research and Cut Jobs
Fed Rate Cut Tailwind, Lilly’s Triple Agonist Delivers Big, Vaccine Policy Turmoil — This Week in Biotech #81
Hiring Outlook: February Brings First YOY Job Increase Since 2022
America Is Losing the Innovation Race
Poland, Romania Ordered to Honor Vaccine Deal with Pfizer
Ongoing Regulatory Uncertainty Means Innovation Is Now Higher Risk
FDA Policy Tracker 2026: Priority Vouchers Questioned, PRVs Return
BioNTech’s Multi-Modality Play Outpaces Moderna’s mRNA-Focused Pipeline
Being Specific About Being General: Vaccines Edition
UK Names Health Data Chief, as BIA Finds Its New CEO
Pfizer, BioNTech Abort U.S. Updated COVID-19 Vaccine Trial as Enrollment Falters
BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast
Pan Cancer T Raises €10M in Funding
Rare Disease Advocacy Group Urges Trump Administration to Restore FDA Clarity
#JPM26: Moderna CEO Bancel Talks Deals, Flu and RSV Strategy
U.S. Vaccine Approvals to Undergo Overhaul: What Do the Changes Mean?
Brinsupri Setback Slices Insmed Market Cap — Clinical Report
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine
Cassidy Names Areas of Improvement for FDA’s Regulatory ‘Black Box’
Moderna, Merck Show Long-Term Survival For mRNA-Keytruda Combo
Maternal COVID-19 Vaccination Protects Infants for up to 6 Months
Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M
2024-2025 COVID-19 Vaccines Provided Moderate Protection Against JN.1 Variants
GSK Delivers in New CEO Miels' First Financial Update
Moderna Licenses Phase 3 Asset to Recordati; ProMIS' Private Placement
Officials ‘Missed 99% of Data’ on Covid Vaccines Before Making Recommendation, Memos Reveal
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
What Sanofi’s Multiple Sclerosis Troubles Could Mean for the Space
BioNTech Cofounders To Step Down. Stock Crumbles.
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
